Business Context and Reporting Period
This Form 8-K, dated March 4, 2024, reports that Akari Therapeutics, Plc ("Akari") entered into a definitive Agreement and Plan of Merger with Peak Bio, Inc. ("Peak Bio"). Under the agreement, a wholly-owned subsidiary of Akari will merge with and into Peak Bio, with Peak Bio surviving as a wholly-owned subsidiary of Akari. The transaction is structured as a stock-for-stock exchange.
Key Financial Metrics and Transaction Terms
The filing does not provide historical revenue, profit, or cash flow data for either company. Key financial terms of the transaction include:
- Exchange Ratio: Peak Bio shareholders will receive Akari American Depositary Shares (ADSs) representing approximately 50% of the outstanding Akari ADSs upon issuance, subject to adjustments based on net cash positions.
- PIPE Investment: A condition of closing is the consummation of a PIPE investment resulting in net proceeds to Akari of at least $10,000,000.
- Net Cash Condition: Closing is conditioned on the other party's net cash being greater than negative $13,500,000.
- Termination Fees: In certain termination scenarios, a fee of $300,000 is payable, along with reimbursement of transaction expenses up to $1.5 million.
Material Changes and Conditions
The primary material change is the proposed combination of Akari and Peak Bio. The transaction is subject to several material conditions, including:
- Approval by Peak Bio stockholders and Akari shareholders.
- Effectiveness of Akari's Registration Statement on Form S-4.
- Authorization for listing of Akari ADSs on Nasdaq.
- Absence of laws or orders prohibiting the merger.
- Completion of the PIPE investment.
Shareholder support agreements have been executed with holders representing approximately 39.51% of Akari's outstanding shares and 39.3% of Peak Bio's outstanding shares as of March 1, 2024.
Guidance, Outlook, and Risks
The filing contains extensive forward-looking statements regarding the anticipated benefits of the merger, including combined operations and product development. However, no specific financial guidance or revenue projections are provided in this document. Key risks and contingencies include:
- Termination Deadlines: The agreement may be terminated if the merger is not completed by September 4, 2024.
- Regulatory and Approval Risks: Failure to obtain necessary shareholder approvals or regulatory clearances.
- Competing Proposals: The boards may withdraw recommendations if a superior proposal is received.
- Operational Risks: Uncertainties regarding the development of product candidates, clinical trial outcomes, and the ability to retain key personnel.
Investor Verification Checklist
- Verify the final Exchange Ratio and any adjustments based on net cash positions at closing.
- Confirm the status and terms of the PIPE investment required to meet the $10 million net proceeds condition.
- Monitor the filing and effectiveness of the Form S-4 Registration Statement and Joint Proxy Statement/Prospectus.
- Review the specific terms of the Voting Agreements to understand the level of committed shareholder support.
- Assess the net cash positions of both companies to ensure they meet the negative $13.5 million threshold.